close
close

CureVac partner GSK announces positive phase 2 data from seasonal influenza mRNA vaccine program

CureVac partner GSK announces positive phase 2 data from seasonal influenza mRNA vaccine program

(“CureVac”), a global biopharmaceutical company developing a novel class of transformative medicines based on messenger ribonucleic acid…